Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Andrew Stefka, MS, David Johnson, Shaun Rosebeck, PhD, Jae-Hyun Park, DVM, PhD, Yusuke Nakamura, MD, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 4415.

https://doi.org/10.1182/blood.V130.Suppl_1.4415.4415

Published: 2017

Journal Articles

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Todd Zimmerman, MD, Noopur S. Raje, Ravi Vij, Donna Reece, MD, Jesus G. Berdeja, MD, Leonor A Stephens, PhD, Kathryn McDonnell, Cara A. Rosenbaum, MD, Jagoda Jasielec, MD, Paul G Richardson, MD, Sandeep Gurbuxani, Jennifer Nam, Erica Severson, Brittany D. Wolfe, MMS, PA-C, Shaun Rosebeck, PhD, Andrew Stefka, Dominik Dytfeld, MD PhD, Kent Griffith, PhD, Andrzej Jakubowiak, MDPhD

Blood (2016) 128 (22): 675.

https://doi.org/10.1182/blood.V128.22.675.675

Published: 2016

Journal Articles

Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MDPhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Erica Severson, Leonor A Stephens, PhD, Kathryn McDonnell, Shaun Rosebeck, PhD, Todd Zimmerman, MD, Theodore Karrison, PhD, Jeffrey Zonder, MD

Blood (2016) 128 (22): 973.

https://doi.org/10.1182/blood.V128.22.973.973

Published: 2016

Journal Articles

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Jeffrey A Zonder, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Leonor A Stephens, PhD, Kathryn McDonnell, Rebecca Uribe, Shaun Rosebeck, PhD, Tami Rashal, MD, Hagop Youssoufian, MD, Sarah Henry, Sharon Shacham, Michael Kauffman, MD PhD, Todd Zimmerman, MD, Theodore Karrison, PhD

Blood (2015) 126 (23): 4223.

https://doi.org/10.1182/blood.V126.23.4223.4223

Published: 2015

Journal Articles

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, PhD, Tara Anderson, Melissa Mietzel, Malek Faham, Liana Lee, Joan Levy, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark Kaminski, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2127.

https://doi.org/10.1182/blood.V124.21.2127.2127

Published: 2014

Journal Articles

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Martin van Vliet, PhD, Jagoda Jasielec, MD, Dominik Dytfeld, MD PhD, Ravi Vij, MD, Belinda Dumee, BSc, Lizanne Bosman, BSc, Leonie C.M. deBest, MSc, Mattina Alonge, MS, Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Kathryn McDonnell, BS, Kent A. Griffith, Erik H van Beers, PhD, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2141.

https://doi.org/10.1182/blood.V124.21.2141.2141

Published: 2014

Journal Articles

Anti-Myeloma Activity of Combined Inhibition of the Proteasome with Carfilzomib (CFZ) and XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330) Via a Novel Mechanism of Intracellular Activation of Caspase 10-Dependent Apoptosis

Shaun Rosebeck, PhD, Mattina Alonge, MS, Jagoda Jasielec, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 3443.

https://doi.org/10.1182/blood.V124.21.3443.3443

Published: 2014

Journal Articles

Gene Expression and Transcription Factor (TF) Activation Profiling Identifies Suppression of Multiple Myeloma (MM) Cell Survival and Chemoresistance Pathways By Inhibition of XPO1/CRM1-Dependent Nuclear Export with Selinexor

Shaun Rosebeck, PhD, Mattina Alonge, MS, Jagoda Jasielec, Anoop Mayampurath, PhD, Samuel L. Volchenboum, MD PhD, Sharon Shacham, PhDMBA, Michael Kauffman, MD PhD, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 3444.

https://doi.org/10.1182/blood.V124.21.3444.3444

Published: 2014

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Mattina M. Alonge, Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Sean P Maxwell, Stephanie J Kraftson, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 279.

https://doi.org/10.1182/blood.V122.21.279.279

Published: 2013

NARROW

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Anti-Myeloma Activity of Combined Inhibition of the Proteasome with Carfilzomib (CFZ) and XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330) Via a Novel Mechanism of Intracellular Activation of Caspase 10-Dependent Apoptosis

Gene Expression and Transcription Factor (TF) Activation Profiling Identifies Suppression of Multiple Myeloma (MM) Cell Survival and Chemoresistance Pathways By Inhibition of XPO1/CRM1-Dependent Nuclear Export with Selinexor

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only